Mandate

Vinge has advised Oncopeptides in connection with entering into renewed agreements regarding a loan facility of up to EUR 30 million from the European Investment Bank

The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.

Oncopeptides is a biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company´s lead product is approved on several markets for treatment of adult patients with multiple myeloma. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Louise Brorsson Salomon, Arvid Weimers and Kamyar Najmi (finance) as well as Dain Hård Nevonen and Linnéa Sellström (capital markets).

Related

Vinge advises Setra Trävaror in conjunction with the sale of Malå Såg to HS Timber

The Austrian company HS Timber Group has entered into an agreement to acquire 100 per cent of the shares in the Swedish wood processing company Malå Såg AB from Setra Trävaror AB, a subsidiary of Setra Group AB. The transaction remains subject to approval from the relevant public authorities.
October 29, 2025

Vinge has advised Advania on the acquisition of Visuell Teknik

Advania has acquired Visuell Teknik, a Swedish provider of audiovisual and meeting technology solutions.
October 28, 2025

Vinge has advised Acrinova in connection with voluntary share redemption offering

Vinge has advised Acrinova AB (publ) in connection with its voluntary share redemption offering. The offer comprised approximately one-third of the shares in Acrinova, and the acceptance rate reached approximately 97.34 percent, representing a redemption value of approximately SEK 367.4 million.
October 27, 2025